Therapeutic area intelligence for LDL-C Lowering with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

Merck →

Assets

Enlicitide →

evolocumab →

Recent signals(3)

ClinicalAugust 6, 2026

CAPRA-EVO Trial Evaluates Early Evolocumab in Acute Coronary Syndrome Patients

The CAPRA-EVO trial is assessing the efficacy of early evolocumab in reducing coronary plaque progression in ACS patients.

ClinicalJune 24, 2026

Novartis initiates trial for inclisiran in acute coronary syndromes

Novartis is evaluating inclisiran's efficacy and safety in patients with acute coronary syndromes, initiated early in the hospital.

ClinicalJune 24, 2026

Merck's Enlicitide Study Aims to Enhance LDL-C Reduction with Rosuvastatin

Merck is conducting a clinical trial to evaluate the efficacy of enlicitide in combination with rosuvastatin for lowering LDL-C levels.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.